These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 11433759)
1. [Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer]. Kotake T; Akaza H; Usami M; Naito S; Kanetake H; Taguchi T; Tsukagoshi S; Koiso K Hinyokika Kiyo; 2001 May; 47(5):349-61. PubMed ID: 11433759 [TBL] [Abstract][Full Text] [Related]
2. [A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies]. Tsukagoshi S Gan To Kagaku Ryoho; 2002 Sep; 29(9):1675-87. PubMed ID: 12355959 [TBL] [Abstract][Full Text] [Related]
3. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients]. Koiso K; Yamanaka H; Ito K; Yoshinaka R; Uchida S; Yokokawa K Hinyokika Kiyo; 2002 Dec; 48(12):771-9. PubMed ID: 12613015 [TBL] [Abstract][Full Text] [Related]
4. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies]. Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044 [TBL] [Abstract][Full Text] [Related]
5. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system. Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z Neoplasma; 1997; 44(5):308-13. PubMed ID: 9473791 [TBL] [Abstract][Full Text] [Related]
6. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma]. Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179 [TBL] [Abstract][Full Text] [Related]
7. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. Crawford ED; Sartor O; Chu F; Perez R; Karlin G; Garrett JS J Urol; 2006 Feb; 175(2):533-6. PubMed ID: 16406989 [TBL] [Abstract][Full Text] [Related]
8. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients]. Koiso K; Akaza H; Naito S; Usami M; Tsukamoto T; Shimazaki J; Kotake T; Yamanaka H; Oohashi Y; Yoshinaka R; Onouchi H; Yokokawa K Hinyokika Kiyo; 2002 Dec; 48(12):781-95. PubMed ID: 12613016 [TBL] [Abstract][Full Text] [Related]
9. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study. Pathak AS; Pacificar JS; Shapiro CE; Williams SG J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298 [TBL] [Abstract][Full Text] [Related]
10. Long-term clinical study on luteinising hormone-releasing hormone agonist depot formulation in the treatment of stage D prostatic cancer. The TAP-144-SR Study Group. Akaza H; Usami M; Koiso K; Kotake T; Aso Y; Niijima T Jpn J Clin Oncol; 1992 Jun; 22(3):177-84. PubMed ID: 1518166 [TBL] [Abstract][Full Text] [Related]
11. Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial. Zinner NR; Bidair M; Centeno A; Tomera K Urology; 2004 Dec; 64(6):1177-81. PubMed ID: 15596193 [TBL] [Abstract][Full Text] [Related]
12. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer. Bong GW; Clarke HS; Hancock WC; Keane TE Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929 [TBL] [Abstract][Full Text] [Related]
13. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer. Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637 [TBL] [Abstract][Full Text] [Related]
14. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR]. Niijima T; Aso Y; Akaza H; Fujita K; Fuse H; Hosaka M; Isurugi K; Kamidono S; Katayama T; Kawabe K Hinyokika Kiyo; 1990 Nov; 36(11):1343-60. PubMed ID: 2126912 [TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858 [TBL] [Abstract][Full Text] [Related]
16. Final report on low-dose estramustine phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer. Kitamura T; Suzuki M; Nishimatsu H; Kurosaki T; Enomoto Y; Fukuhara H; Kume H; Takeuchi T; Miao L; Jiangang H; Xiaoqiang L Aktuelle Urol; 2010 Jan; 41 Suppl 1():S34-40. PubMed ID: 20094950 [TBL] [Abstract][Full Text] [Related]
17. [Dynamic study of the hormonal levels and tumor markers after the first administration of long-acting LH-RH analogue in patients with prostate cancer]. Takeuchi S; Yoshida K; Tosaka A; Kobayashi N; Uchijima Y; Saitoh H Hinyokika Kiyo; 1994 May; 40(5):393-400. PubMed ID: 7517620 [TBL] [Abstract][Full Text] [Related]
18. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer. Kobayashi T; Nishizawa K; Mitsumori K Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259 [TBL] [Abstract][Full Text] [Related]
19. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145 [TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer. Ozono S; Ueda T; Hoshi S; Yamaguchi A; Maeda H; Fukuyama Y; Takeda K; Ohashi Y; Tsukamoto T; Naito S; Akaza H Jpn J Clin Oncol; 2012 Jun; 42(6):477-84. PubMed ID: 22457321 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]